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Screening mammography aims to identify breast cancer before symptoms appear, 29 
enabling earlier therapy for more treatable disease1. Despite the existence of screening 30 
programmes worldwide, interpretation of mammograms suffers from suboptimal rates of 31 
false positives and false negatives2. Here we present an AI system capable of surpassing 32 
expert readers in breast cancer prediction performance. To assess its performance in the 33 
clinical setting, we curated a large representative dataset from the United Kingdom (UK) 34 
and a large enriched dataset from the United States (US). We show an absolute reduction 35 
of 5.7%/1.2% (US/UK) in false positives and 9.4%/2.7% (US/UK) in false negatives. We 36 
show evidence of the system's ability to generalise from the UK sites to the US site. In an 37 
independently-conducted reader study, the AI system out-performed all six radiologists 38 
with an area under the receiver operating characteristic curve greater than the average 39 
radiologist by an absolute margin of 11.5%. By simulating the AI system's role in the 40 
double-reading process, we maintain noninferior performance while reducing the second 41 
reader's workload by 88%. This robust assessment of the AI system paves the way for 42 
prospective clinical trials to improve the accuracy and efficiency of breast cancer 43 
screening. 44 
 45 
Breast cancer is the second leading cause of cancer death in women3, but early detection and 46 
treatment can dramatically improve outcomes1,4,5. As a consequence, many developed nations 47 
have implemented large-scale mammography screening programmes. Major medical and 48 
governmental organisations recommend screening for all women starting between the ages of 49 
40 and 506–8. In the US and UK combined, over 42 million exams are performed each year9,10. 50 
Despite mammography's widespread adoption, interpretation of these images remains 51 
challenging. There is high variability in experts’ cancer detection accuracy, and the performance 52 
of even the best clinicians leaves room for improvement11,12. False positives can lead to patient 53 
anxiety13, unnecessary follow up, and invasive diagnostic procedures. Cancers missed at 54 
screening may not be identified until they are more advanced and less amenable to treatment14.  55 
Artificial intelligence (AI) may be uniquely poised to help. Recent studies have demonstrated 56 
AI's ability to meet or exceed the performance of human experts on several medical image 57 
analysis tasks15–19. As a shortage of mammography professionals threatens availability and 58 
adequacy of breast screening services around the world20–23, the scalability of AI could improve 59 
access to high quality care for all. 60 
 61 
Computer-aided detection (CAD) software for mammography was introduced in the 1990s, and 62 
multiple assistive tools have been approved for medical use24. Despite early promise25,26, this 63 
generation of software failed to improve reader performance in real-world settings12,27,28. More 64 
recently, the field has seen a renaissance owing to the success of deep learning. A few studies 65 
have shown breast cancer prediction systems with standalone performance approaching that of 66 
human experts29,30. Still, existing work has several limitations. Most studies evaluate on small, 67 
enriched datasets with limited follow-up, and few have compared performance to readers in 68 
actual clinical practice, instead relying on lab-based simulations of the reading environment. To 69 





screening populations and settings without additional training data31. Critically, the pervasive 71 
use of follow-up intervals no longer than 12 months29,30,32,33 means that more subtle cancers, not 72 
identified until the next screen, may be ignored. 73 
In this study, we evaluate the performance of a new AI system for breast cancer prediction 74 
using two large, clinically-representative datasets from the UK and US. We compare the 75 
system’s predictions to those made by readers in routine clinical practice and show performance 76 
better than individual radiologists. These observations are confirmed with an independently-77 
conducted reader study. We further show how this system might be integrated into screening 78 
workflows, and provide evidence that the system can generalise across continents. Figure 1 79 
depicts a high-level overview. 80 
Screening programme datasets 81 
A deep learning model for identifying breast cancer in screening mammograms was developed 82 
and evaluated using two large datasets from the UK and the US. We report results on test sets 83 
withheld from AI development.  84 
 85 
The UK test set consisted of screening mammograms from 25,856 women collected between 86 
2012 and 2015 at two screening centers in England, where women are screened every three 87 
years. It included 785 women who had a biopsy, and 414 women with cancer diagnosed within 88 
39 months (3 years and 3 months) of imaging. This was a random sample of 10% of all women 89 
with screening mammograms at these sites during this time period. The UK cohort resembled 90 
the broader screening population in age and disease characteristics (Extended Data Table 1a). 91 
 92 
The test set from the US, where women are screened every 1 or 2 years, consisted of screening 93 
mammograms from 3,097 women collected between 2001 and 2018 at one academic medical 94 
center. We included images from all 1,511 women biopsied during this time period and a 95 
random subset of women who never underwent biopsy (Methods). Among the women who 96 
received a biopsy, 686 were diagnosed with cancer within 27 months (2 years and 3 months) of 97 
imaging. 98 
 99 
Breast cancer outcome was determined on the basis of multiple years of follow up (Figure 1). 100 
We chose the follow-up duration based on the screening interval in each dataset’s country of 101 
origin. Following previous work34, we augment each interval with a 3-month buffer to account for 102 
variability in scheduling and latency of follow up. Cases designated as cancer positive were 103 
accompanied by a biopsy-confirmed diagnosis within the follow-up period. Cases labeled as 104 
cancer negative had at least one follow-up non-cancer screen; cases without this follow up were 105 





Retrospective clinical comparison 107 
We used biopsy-confirmed breast cancer to evaluate predictions of the AI system as well as the 108 
original decisions made by radiologists in the course of clinical practice. Human performance 109 
was computed based on the clinician’s decision to recall the patient for further diagnostic 110 
investigation. The receiver operating characteristic (ROC) curve of the AI system’s cancer 111 
prediction is shown in Figure 2.  112 
 113 
In the UK, each mammogram is interpreted by two readers. In cases of disagreement, an 114 
arbitration process is used, invoking a third opinion. These interpretations occur serially such 115 
that each reader has access to prior readers’ opinions. The records of these decisions yield 116 
three human performance benchmarks for cancer prediction.  117 
 118 
Compared to the first reader, the AI system demonstrated a statistically significant absolute 119 
specificity improvement of 1.2% (95% CI [0.29%, 2.1%]; p = 0.0096 for superiority) and an 120 
absolute sensitivity improvement of 2.7% (95% CI [-3%, 8.5%]; p = 0.004 for noninferiority at a 121 
prespecified 5% margin; Extended Data Table 2a). 122 
 123 
Compared to the second reader, the AI system showed non-inferiority (at a 5% margin) for both 124 
specificity (p < 0.001) and sensitivity (p = 0.02). The AI system likewise showed non-inferiority 125 
(at a 5% margin) to the consensus judgment for specificity (p < 0.001) and sensitivity (p = 126 
0.0039). 127 
 128 
In the standard US screening protocol, each mammogram is interpreted by a single radiologist. 129 
We used the BI-RADS35 score assigned to each case in the original screening context as a 130 
proxy for the human cancer prediction (Methods, Interpreting clinical reads). Compared to the 131 
typical reader, the AI system demonstrated statistically significant improvements in absolute 132 
specificity of 5.7% (95% CI [2.6%, 8.6%]; p < 0.001) and sensitivity of 9.4% (95% CI [4.5%, 133 
13.9%]; p < 0.001; Extended Data Table 2a).  134 
Generalisation across populations 135 
To evaluate the AI system’s ability to generalise across populations and screening settings, we 136 
trained the same architecture using only the UK dataset and applied it to the US test set (Figure 137 
2b). Even without exposure to US training data, the AI system’s ROC curve envelops the point 138 
indicating the average performance of US radiologists. Once again, the AI system showed 139 
superior specificity (+3.5%, p = 0.0212) and superior sensitivity (+8.1%, p = 0.0006; Extended 140 
Data Table 2b). 141 
Reader study comparison 142 
In a reader study conducted by an external clinical research organisation, six US board-certified 143 





interpreted 500 mammograms randomly sampled from the US test set. Where data were 145 
available, readers were equipped with contextual information typically available in the clinical 146 
setting, including patient age, breast cancer history, and prior screening mammograms. 147 
 148 
Among the 500 cases selected for this study, 125 had biopsy-proven cancer within 27 months, 149 
125 had a negative biopsy within 27 months, and 250 were not biopsied (Extended Data Table 150 
3). These proportions were chosen to increase the difficulty of the screening task and increase 151 
statistical power; such enrichment is typical in observer studies36. 152 
 153 
Readers rated each case using the forced BI-RADS35 scale. BI-RADS scores were compared to 154 
ground truth outcomes to fit an ROC curve for each reader. The scores of the AI system were 155 
treated in the same manner (Extended Data Table 2). 156 
 157 
The AI system exceeded average radiologist performance by a significant margin (∆AUC = 158 
+0.115, 95% CI: [0.055, 0.175], p = 0.0002). Similar results were observed when 1 year follow-159 
up was used instead of 27 months (Figure 3c, Extended Data Figure 2). 160 
 161 
In addition to producing case-level classification, the AI system was designed to highlight areas 162 
of suspicion for malignancy. Likewise, the readers in our study supplied rectangular region-of-163 
interest (ROI) annotations surrounding concerning findings. 164 
 165 
We used multi-localisation receiver operating characteristic (mLROC) analysis37 to compare the 166 
ability of the readers and the AI system to identify malignant lesions within each case (Methods, 167 
Localisation analysis). 168 
 169 
We summarised each mLROC plot by computing the partial area under the curve (pAUC) in the 170 
false positive fraction interval from 0 to 0.138 (Extended Data Figure 3). The AI system exceeded 171 
human performance by a significant margin (∆pAUC = +0.0192, 95% CI: [0.0086, 0.0298], p = 172 
0.0004). 173 
Potential clinical applications 174 
The AI system’s classifications could be used to reduce the workload involved in the UK’s 175 
double reading process while preserving the standard of care. We explored this scenario 176 
through simulation by omitting the second reader and any ensuing arbitration when the AI’s 177 
decision agreed with the first reader. In these cases, the first reader’s opinion was treated as 178 
final. In cases of disagreement, the second and consensus opinions were invoked as usual. 179 
This combination of human and machine displays performance equivalent to that of the 180 
traditional double reading process, while saving 88% of the second reader’s effort (Extended 181 
Data Table 4a). 182 
 183 
The AI system could also be used to provide automated, immediate feedback in the screening 184 






In order to identify normal cases with high confidence, we used a very low decision threshold. 187 
On the UK data, we achieved a negative predictive value (NPV) of 99.99% while retaining a 188 
specificity of 41.15%. Similarly, on the US data, we achieved a NPV of 99.90% while retaining a 189 
specificity of 34.79%. These data suggest that it may be feasible to pick out 35–41% of normal 190 
cases if we allow for one cancer in every 1,000–10,000 negative predictions (NPV 99.90–191 
99.99% in US–UK). For comparison, consensus double reading in our UK dataset included one 192 
cancer in every 182 cases deemed normal. 193 
 194 
To identify cancer cases with high confidence, we used a very high decision threshold. On the 195 
UK data, we achieved a positive predictive value (PPV) of 85.6% while retaining a sensitivity of 196 
41.2%. Likewise, on the US data, we achieved a PPV of 82.4% while retaining a sensitivity of 197 
29.8%. These data suggest that it may be feasible to rapidly prioritise 30–40% of cancer cases 198 
with approximately 5 of 6 follow ups leading to cancer diagnosis. By comparison, in our study 199 
only 22.8% of UK cases recalled by consensus double reading and 4.9% of US cases recalled 200 
by single reading were ultimately diagnosed with cancer. 201 
Performance breakdown 202 
Comparing the errors of the AI system with errors from clinical reads revealed many cases in 203 
which the AI system correctly identified cancer while the reader did not and vice versa 204 
(Supplementary Table 1). Most of the cases in which only the AI system identified cancer were 205 
invasive (Extended Data Table 5). On the other hand, cases in which only the reader identified 206 
cancer were split more evenly between in situ and invasive. Further breakdowns by invasive 207 
cancer size, grade, and molecular markers show no clear biases (Supplementary Table 2). 208 
 209 
We also considered the disagreement between the AI system and the six radiologists that 210 
participated in the US reader study. Figure 4a shows a sample cancer case missed by all six 211 
radiologists, but correctly identified by the AI system. Figure 4b shows a sample cancer case 212 
caught by all six radiologists but missed by the AI system. While we were unable to determine 213 
clear patterns among these instances, the presence of such edge cases suggests potentially 214 
complementary roles for the AI system and human readers in reaching accurate conclusions. 215 
 216 
We compared the performance of the 20 individual readers best represented in the UK clinical 217 
dataset with that of the AI system (Extended Data Table 7). The results of this analysis suggest 218 
that the aggregate comparison presented above is not unduly influenced by any particular 219 
readers. Breakdowns by cancer type, grade, and lesion size suggest no apparent difference in 220 
the distribution of cancers detected by the AI system and human readers (Extended Data Table 221 
6a). 222 
 223 
On the US test set, a breakdown by cancer type (Extended Data Table 6b) shows that the AI 224 
system's sensitivity advantage is concentrated on the identification of invasive cancers (e.g. 225 





breakdown by BI-RADS35 breast density category shows that performance gains apply equally 227 
across the spectrum of breast tissue types represented in this data set (Extended Data Table 228 
6c). 229 
Discussion 230 
In this study we present an AI system that outperforms radiologists on a clinically relevant 231 
breast cancer identification task. These results held on two large datasets representative of 232 
different country-specific screening populations and practices. 233 
In the UK, the AI system showed specificity superior to that of the first reader. Sensitivity at the 234 
same operating point was noninferior. Consensus double reading has been shown to improve 235 
performance compared to single reading39, and represents the current standard of care in the 236 
UK and many European countries40. Our system did not outperform this benchmark, but was 237 
statistically noninferior to the second reader and consensus opinion. 238 
In the US, the AI system displayed specificity and sensitivity superior to that of radiologists 239 
practicing in an academic medical center. This trend was confirmed in an externally conducted 240 
reader study, which showed that the scores of the AI system stratify cases better than each of 241 
the six readers’ BI-RADS ratings, the standard scale for mammography assessment in the US. 242 
Remarkably, the human readers (both in the clinic and our reader study) had access to patient 243 
history and prior mammograms when making screening decisions. The US clinical readers may 244 
have also had access to breast tomosynthesis images. In contrast, the AI system only 245 
processed the most recent mammogram. 246 
These comparisons are not without limitations. While the UK dataset mirrored the nationwide 247 
screening population in age and cancer prevalence (Extended Data Table 1a), the same cannot 248 
be said of the US data, which was drawn from a single screening centre and was enriched for 249 
cancer cases.  250 
By chance, the vast majority of images used in this study were acquired on devices made by 251 
Hologic, Inc. Future research should assess the AI system’s performance across a variety of 252 
manufacturers in a more systematic way. 253 
In our reader study, all the radiologists were eligible to interpret screening mammograms in the 254 
US, but did not uniformly receive fellowship training in breast imaging. It is possible that a higher 255 
performance benchmark could have been obtained with more specialised readers41. 256 
To obtain high-quality ground-truth labels, we employed extended follow-up intervals chosen to 257 
encompass a subsequent screening round in each country. Although there is some precedent in 258 
clinical trials34 and targeted cohort studies42, this step is not usually taken when undertaking 259 





In retrospective datasets with shorter follow-up intervals, outcome labels tend to be skewed in 261 
favour of readers. Since they are gatekeepers for biopsy, asymptomatic cases will only receive 262 
a cancer diagnosis if a mammogram raised reader suspicion. A longer follow-up interval 263 
decouples the ground truth labels from reader opinions (Extended Data Figure 4) and includes 264 
cancers that may have been initially missed by human eyes. 265 
The use of an extended interval makes cancer prediction a more challenging task. Cancers 266 
diagnosed years later may include new growths for which there could be no mammographic 267 
evidence in the original images. Consequently, the sensitivity values presented here are lower 268 
than what has been reported for 12 month intervals2 (Extended Data Figure 5). 269 
We present early evidence of the AI system's ability to generalise across populations and 270 
screening protocols. We retrained the system using exclusively UK data, and then measured 271 
performance on unseen US data. In this context, the system continued to outperform 272 
radiologists, albeit by a smaller margin. This suggests that in future clinical deployments, the 273 
system might offer strong baseline performance, but may benefit from fine-tuning with local 274 
data. 275 
The utility of the AI system within clinical workflows remains to be determined. The specificity 276 
advantage exhibited by the AI system suggests it could help reduce recall rates and 277 
unnecessary biopsies. The improvement in sensitivity, exhibited in the US data, shows that the 278 
AI system may be capable of detecting cancers earlier than the standard of care. An analysis of 279 
the AI system’s localisation performance suggests the early promise of using it to flag 280 
suspicious regions for review by experts. Notably, the additional cancers identified tended to be 281 
invasive rather than in situ disease. 282 
Beyond augmenting reader performance, the technology described here may have a number of 283 
other clinical applications. Through simulation, we suggest how the system could obviate the 284 
need for double reading in 88% of UK screening cases, while maintaining similar accuracy to 285 
the standard protocol. We also explore how high-confidence operating points can be used to 286 
triage high-risk cases and dismiss low-risk cases. These analyses highlight the potential of this 287 
technology to deliver screening results in a sustainable manner despite workforce challenges in 288 
countries like the UK43. Prospective clinical studies will be required to understand the full extent 289 
to which this technology can benefit patient care. 290 
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Figure 1. Development of an AI system to detect cancer in screening mammograms.  399 
Datasets representative of the UK and US breast cancer screening populations were curated 400 
from three screening centers in the UK and one center in the US. Outcomes were derived from 401 
the biopsy record and longitudinal follow up. An AI system was trained to identify the presence 402 
of breast cancer from a screening mammogram; it was evaluated in three primary ways. AI 403 
predictions were compared with the historical decisions made in clinical practice. To evaluate 404 
the generalisability across populations, a version of the AI system was developed using only the 405 
UK data and retested on the US data. Finally, the AI system was compared with six 406 
independent radiologists using a subset of the US test set. 407 
 408 
Figure 2. Breast cancer prediction performance. 409 
a. Receiver operating characteristic (ROC) curve of the AI system on the UK screening data. 410 
The area under the curve (AUC) is 0.889 (95% CI [0.871, 0.907]; n = 25,856 patients). Also 411 
shown are the (sensitivity, specificity) pairs of the human decisions made in clinical practice. 412 
Cases were considered positive if they received a biopsy-confirmed cancer diagnosis within 39 413 
months (3 years and 3 months) from the time of screening. The consensus decision represents 414 
the standard of care in the UK, and will involve input from between 2 and 3 expert readers. The 415 
inset shows an enhancement of the gray shaded region. AI system operating points were 416 
selected on a separate validation dataset: point (i) was intended to match the sensitivity and 417 
exceed the specificity of the first reader; points (ii) and (iii) were selected to attain non-inferiority 418 
for both the sensitivity and specificity of the second reader and consensus opinion, respectively. 419 
b. ROC curve of the AI system on the US screening data. When trained on both datasets, the 420 
AUC is 0.8107 (95% CI [0.791, 0.831]; n = 3,097 patients). When trained only on the UK dataset 421 
(dotted curve), the AUC is 0.757 (95% CI [0.732, 780]). Also shown are the sensitivity and 422 
specificity achieved by radiologists in clinical practice using BI-RADS35. Cases were considered 423 
positive if they received a biopsy-confirmed cancer diagnosis within 27 months (2 years and 3 424 
months) from the time of screening. AI system operating points were chosen to exceed the 425 
average reader’s sensitivity and specificity. Negative cases were upweighted to account for the 426 
sampling protocol (Methods, Inverse probability weighting). Extended Data Figure 1 shows an 427 
unweighted analysis. See Extended Data Table 2a for statistical comparisons of sensitivity and 428 
specificity.  429 
 430 
Figure 3. Breast cancer prediction performance compared to six independent readers. 431 
a. Six readers rated each case (n = 465) using the 6-point BI-RADS scale. A fitted ROC curve 432 
for each of the readers is compared to the ROC curve of the AI system (Methods, Statistical 433 
analysis). For reference, a nonparametric ROC curve is presented in tandem. Cases were 434 
considered positive (n = 113) if they received a pathology-confirmed cancer diagnosis within 27 435 
months (2 years and 3 months) from the time of screening. Note that this sample of cases was 436 
enriched for patients that had received a negative biopsy result (n = 119), making this a more 437 
challenging population for screening. The mean reader AUC was 0.625 (s.d. 0.032), while the AI 438 





performance by a significant margin (∆ = +0.115, 95% CI: [0.055, 0.175], p = 0.0002, two-sided 440 
ORH method). For results using a 12-month interval, see Extended Data Figure 2. 441 
b. Pooled results from all six readers from (a). 442 
c. Pooled results (n = 408) from all six readers using a 12-month interval for cancer definition. 443 
Cases were considered positive (n = 56) if they received a pathology-confirmed cancer 444 
diagnosis within 1 year (Extended Data Table 3). 445 
 446 
Figure 4. Discrepancies between the AI system and human readers. 447 
a. A sample cancer case missed by all six readers in the US reader study, but correctly 448 
identified by the AI system. The images show two views of a small, irregular mass with 449 
associated microcalcifications in the lower inner right breast. 450 
b. A sample cancer case caught by all six readers in the US reader study, but missed by the AI 451 
system. The images show two views of a dense mass in the lower inner right breast.  452 
(left, mediolateral oblique; right, craniocaudal) 453 
 454 






Ethical approval. Use of the UK dataset for research collaborations by both commercial and 457 
non-commercial organisations received ethical approval (REC reference 14/SC/0258). The US 458 
data was fully de-identified and released only after an Institutional Review Board approval 459 
(STU00206925). 460 
 461 
UK dataset. The UK dataset was collected from three breast screening sites in the United 462 
Kingdom National Health Service Breast Screening Programme (NHSBSP). The NHSBSP 463 
invites women aged between 50 and 70 who are registered with a general practitioner (GP) for 464 
mammographic screening every 3 years. Women who are not registered with a GP, or who are 465 
older than 70, can self-refer to the screening programme. In the UK, the screening programme 466 
uses double reading: each mammogram is read by two radiologists, who are asked to decide 467 
whether to recall the woman for additional followup. When there is disagreement, an arbitration 468 
process takes place. 469 
 470 
The data was initially compiled by OPTIMAM, a Cancer Research UK effort, between the years 471 
of 2010 and 2018 from St. George’s Hospital (London, UK), Jarvis Breast Centre (Guildford, 472 
UK) and Addenbrooke's Hospital (Cambridge, UK). The collected data included screening and 473 
follow-up mammograms (comprising mediolateral oblique “MLO” and craniocaudal “CC” views 474 
of the left and right breast), all radiologist opinions (including the arbitration result, if applicable) 475 
and metadata associated with follow-up treatment.  476 
 477 
The mammograms and associated metadata of 137,291 women were considered for inclusion 478 
in the study. Of these, 123,964 had both screening images and uncorrupted metadata. Exams 479 
that were recalled for reasons other than radiographic evidence of malignancy, or episodes that 480 
were not part of routine screening were excluded. In total, 121,850 women had at least one 481 
eligible exam. Women who were aged below 47 at the time of the screen were excluded from 482 
validation and test sets, leaving 121,455 women. Finally, women for whom there was insufficient 483 
follow up for any scan were excluded from validation and test. This last step resulted in the 484 
exclusion of 5,990 of 31,766 test set cases (19%). See Supplementary Figure 1.  485 
 486 
The test set is a random sample of 10% of all women screened at two sites, St. George’s and 487 
Jarvis, between the years 2012 and 2015. Insufficient data was provided to apply the sampling 488 
procedure to the third site. In assembling the test set, we randomly selected a single eligible 489 
screening mammogram from each woman’s record. For women with a positive biopsy, eligible 490 
mammograms were those conducted in the 39 months (3 years and 3 months) prior to the 491 
biopsy date. For women that never had a positive biopsy, eligible mammograms were those 492 
with a non-suspicious mammogram at least 21 months later. 493 
 494 
The final test set consisted of 25,856 women (see Supplementary Figure 1). When compared to 495 
the UK national breast cancer screening service we see a very similar cancer prevalence, age 496 





predominantly on devices manufactured by Hologic, Inc. (95%), followed by General Electric 498 
(4%) and Siemens (1%). 499 
 500 
US dataset. The US dataset was collected from Northwestern Memorial Hospital (Chicago, IL) 501 
between the years of 2001 and 2018. In the US, each screening mammogram is typically read 502 
by a single radiologist, and screens are conducted annually or biannually. The breast 503 
radiologists at this hospital are fellowship-trained and only interpret breast imaging studies. 504 
Their experience levels ranged from 1-30 years. The American College of Radiology (ACR) 505 
recommends that women start routine screening at the age of 40, while other organizations 506 
including the US Preventive Services Task Force (USPSTF) recommend initiation at 50 for 507 
women with average breast cancer risk6–8. 508 
 509 
The US dataset included records from all women that underwent a breast biopsy between 2001 510 
and 2018. It also included a random sample of approximately 5% of all women who participated 511 
in screening, but were never biopsied. This heuristic was employed in order to capture all 512 
cancer cases (to enhance statistical power) and to curate a rich set of benign findings on which 513 
to train and test the AI system.  514 
 515 
Supplementary Figure 2 distills the data processing steps involved in constructing the dataset.  516 
Among women with a completed mammogram order, we collected the records from all women 517 
with a pathology report containing the term “breast”. Among those that lacked such a pathology 518 
report, women whose records bore an International Classification of Diseases (ICD) code 519 
indicative of breast cancer were excluded. Approximately 5% of this unbiopsied negative 520 
population was sampled. After deidentification and transfer, women were excluded if their 521 
metadata was either unavailable or corrupted. The women in the dataset were split randomly 522 
among train (55%), validation (15%) and test (30%). For testing, a single case was chosen for 523 
each woman following a similar procedure as in the UK dataset. In women who underwent 524 
biopsy, we randomly chose a case from the 27 months preceding the date of biopsy. For 525 
women who did not undergo biopsy, one screening mammogram was randomly chosen from 526 
among those with a follow up event at least 21 months later.  527 
 528 
Cases were considered complete if they possessed the four standard screening views 529 
(mediolateral oblique “MLO” and craniocaudal “CC” views of the left and right breast) acquired 530 
for screening intent. Here too, the vast majority of the studies were acquired using Hologic 531 
(including Lorad-branded) devices (99%) while manufacturers Siemens and General Electric 532 
together constituted less than 1% of studies. 533 
 534 
The radiology reports associated with cases in the test set were used to flag and exclude cases 535 
in the test set which depicted breast implants or were recalled for technical reasons. To 536 
compare the AI system against the clinical reads performed at this site, we employed clinicians 537 
to manually extract BI-RADS scores from the original radiology reports. There were some cases 538 
for which the original radiology report could not be located, even if a subsequent cancer 539 





was imported from an outside institution. Such cases were excluded from the clinical reader 541 
comparison. 542 
 543 
Inverse probability weighting. The US test set includes images from all biopsied women, but 544 
only a random subset of women who never underwent biopsy. This enrichment allowed us to 545 
accrue more positives in light of the low baseline prevalence of breast cancer, but led to 546 
underrepresentation of normal cases. We accounted for this sampling process by using inverse 547 
probability weighting to obtain unbiased estimates of human and AI system performance in the 548 
natural screening population44,45. 549 
 550 
We acquired images from 7,522 of the 143,238 women who underwent mammography 551 
screening but had no cancer diagnosis or biopsy record. Accordingly, we upweighted cases 552 
from women who never underwent biopsy by a factor of 19.04. Further sampling occurred when 553 
selecting one case per patient: to enrich for difficult cases, we preferentially chose cases from 554 
the timeframe preceding a biopsy, if one occurred. Although this sampling increases the 555 
diversity of benign findings, it again shifts the distribution from what would be observed in a 556 
typical screening interval. To better reflect the prevalence resulting when negative cases are 557 
randomly selected, we estimated additional factors by Monte Carlo simulation. When choosing 558 
one case per patient with our preferential sampling mechanism, we got 872 cases that were 559 
biopsied within 27 months, and 1,662 cases that were not (Supplementary Figure 2). However, 560 
100 trials of pure random sampling yielded on average 557.54 and 2,056.46 cases, 561 
respectively. Accordingly, cases associated with negative biopsies were down-weighted by 562 
557.54 / 872 = 0.64. Cases that were not biopsied were up-weighted by another 2,056.46 / 563 
1,662 = 1.24, leading to a final weight of 19.04 x 1.24 = 23.61.Cancer positive cases carried a 564 
weight of 1.0. The final sample weights were used in sensitivity, specificity and ROC 565 
calculations. 566 
 567 
Histopathological outcomes. In the UK dataset, benign and malignant classifications, given 568 
directly in the metadata, followed NHSBSP definitions46. To derive the outcomes labels for the 569 
US dataset, pathology reports were reviewed by US board-certified pathologists and 570 
categorized according to the findings they contained. An effort was made to make this 571 
categorization consistent with UK definitions. Malignant pathologies included ductal carcinoma 572 
in situ, microinvasive carcinoma, invasive ductal carcinoma, invasive lobular carcinoma, special 573 
type invasive carcinoma (including tubular, mucinous, and cribriform carcinomas), intraductal 574 
papillary carcinoma, non-primary breast cancers (including lymphoma and phyllodes), and 575 
inflammatory carcinoma. Any woman who received a biopsy resulting in any of these malignant 576 
pathologies was considered to have a diagnosis of cancer. 577 
 578 
Benign pathologies included lobular carcinoma in situ, radial scar, columnar cell changes, 579 
atypical lobular hyperplasia, atypical ductal hyperplasia, cyst, sclerosing adenosis, 580 
fibroadenoma, papilloma, periductal mastitis, and usual ductal hyperplasia. None of these 581 






Interpreting clinical reads. In the UK screening setting, readers categorise mammograms from 584 
asymptomatic women as normal or abnormal, with a third option for technical recall due to 585 
inadequate image quality. An abnormal result at the conclusion of the double reading process 586 
results in further diagnostic workup. We treat mammograms deemed abnormal as a prediction 587 
of malignancy. Cases in which the consensus judgment recalled the patient for technical 588 
reasons were excluded from analysis, as the images were presumed incomplete or unreliable. 589 
Cases in which any single reader recommended technical recall were excluded from the 590 
corresponding reader comparison. 591 
 592 
In the US screening setting, radiologists attach a BI-RADS35 score to each mammogram. A 593 
score of 0 is deemed "incomplete", and will be later refined based on follow up imaging or 594 
repeat mammography to address technical issues. For computation of sensitivity and specificity, 595 
we dichotomized the BI-RADS assessments in line with previous work34. Scores of 0, 4 and 5 596 
were treated as positive predictions if recall was not based on technical grounds and the 597 
recommendation was based on mammographic findings, not solely patient symptoms. Cases of 598 
technical recall were excluded from analysis, as the images were presumed incomplete or 599 
unreliable. BI-RADS scores were manually extracted from the free-text radiology reports. Cases 600 
for which the BI-RADS score was unavailable were excluded from the reader comparison. 601 
 602 
In both datasets, the original readers had access to contextual information normally available in 603 
clinical practice. This includes the patient’s family history of cancer, prior screening and 604 
diagnostic imaging, and radiology or pathology notes from past examinations. In contrast, only 605 
the patient's age was made available to the AI system. 606 
 607 
Overview of the AI system. The AI system consisted of an ensemble of three deep learning 608 
models, each operating on a different level of analysis (individual lesions, individual breasts, and 609 
the full case). Each model produces a cancer risk score between 0 and 1 for the entire 610 
mammography case. The final prediction of the system was the mean of the predictions from 611 
the three independent models. A detailed description of the AI system is available in 612 
Supplementary Methods and Supplementary Figure 3. 613 
 614 
Operating point selection. The AI system natively produces a continuous score representing 615 
the likelihood that cancer is present. To support comparisons with the predictions of human 616 
readers, we thresholded this score to produce analogous binary screening decisions. For each 617 
clinical benchmark, we used the validation set to choose a distinct operating point; this amounts 618 
to a score threshold separating positive and negative decisions. To better simulate prospective 619 
deployment, the test sets were never used in selecting operating points. 620 
 621 
The UK dataset contains three clinical benchmarks--the first reader, second reader, and 622 
consensus. This last decision is the outcome of the double reading process and represents the 623 
standard of care in the UK. For the first reader, we chose an operating point aimed at 624 
demonstrating statistical superiority in specificity and non-inferiority for sensitivity. For the 625 
second reader and consensus reader, we chose an operating point aimed at demonstrating 626 






The US dataset contains a single operating point for comparison, corresponding to the single 629 
radiologist using the BI-RADS rubric for evaluation. In this case, we used the validation set to 630 
choose an operating point aimed at achieving superiority on both sensitivity and specificity. 631 
 632 
Reader study. For the reader study, 6 US board-certified radiologists interpreted a sample of 633 
500 cases from 500 women in the test set. All radiologists were compliant with MQSA 634 
requirements for interpreting mammography and had an average of 10 years of clinical 635 
experience (Extended Data Table 7). Two of them were fellowship-trained in breast imaging. 636 
The sample of cases was stratified to contain 50% normal cases, 25% biopsy negative cases 637 
and 25% of biopsy positive cases. A detailed description of the reader study case composition 638 
can be found in Extended Data Table 3. Readers were not informed of the enrichment levels in 639 
the dataset. 640 
 641 
Readers recorded their assessments on a 21CFR11-compliant electronic case report form 642 
within the Ambra Health (New York, NY) viewer v3.18.7.0R. They interpreted the images using 643 
5MP MSQA-compliant displays. Each reader interpreted the cases in a unique randomized 644 
order. 645 
 646 
For each study, readers were asked to first report a BI-RADS35 5th edition score among 0, 1, 647 
and 2, as if they were interpreting the screening mammogram in routine practice. They were 648 
then asked to render a forced diagnostic BI-RADS score using one of the following values: 1, 2, 649 
3, 4A, 4B, 4C or 5. Readers also gave a finer-grained score between 0 and 100 indicating their 650 
suspicion that the case contains a malignancy.  651 
 652 
In addition to the 4 standard mammographic screening mages, clinical context was provided to 653 
better simulate the screening setting. Readers were presented with the preamble of the 654 
deidentified radiology report produced by the radiologist originally interpreting the study. This 655 
contained information such as the patient’s age and family history of cancer. The information 656 
was manually reviewed to ensure that no impression or findings were included. 657 
 658 
Where possible (in 43% of cases), prior imaging was made available to the readers. Readers 659 
could review up to four sets of prior screening exams, acquired between 1 and 4 years earlier, 660 
accompanied by deidentified radiologist reports. If prior imaging was available, the study was 661 
read twice by each reader--first without the prior information and immediately after, with prior 662 
information present. The system ensured that readers could not update their initial assessment 663 
after the prior information was presented. For cases where prior exams were available, reader 664 
assessment after having reviewed priors was used for the analysis. 665 
 666 
Cases for which at least half of the readers indicated image quality concerns were excluded 667 
from analysis. Cases in which breast implants were noted were excluded as well. The final 668 






Localisation analysis. For this purpose, we considered all screening exams from the reader 671 
study for which cancer developed within 12 months. See Extended Data Table 3 for a detailed 672 
description of how the dataset was constructed. To collect ground truth localisations, two board-673 
certified radiologists inspected each case, using follow-up data to identify the location of 674 
malignant lesions. Instances of disagreement were resolved by one radiologist with fellowship 675 
training in breast imaging. To identify the precise location of the cancerous tissue, radiologists 676 
consulted subsequent diagnostic mammograms, radiology reports, biopsy notes, pathology 677 
reports, and post-biopsy mammograms. Rectangular bounding boxes were drawn around the 678 
locations of subsequent positive biopsies in all views in which the finding was visible. In cases 679 
where no mammographic finding was visible, the location where the lesion later appeared was 680 
highlighted. Of the 56 cancers considered for analysis, location information could be obtained 681 
with confidence in 53 cases. Three cases were excluded due to ambiguity in the index 682 
examination and the absence of follow-up images. On average, there were 2.018 ground truth 683 
regions per cancer-positive case. 684 
 685 
In the reader study, readers supplied rectangular region-of-interest (ROI) annotations 686 
surrounding suspicious findings in all cases they rated BI-RADS 3 or higher. A limit of 6 ROIs 687 
per case was enforced. On average, the readers supplied 2.04 annotations per suspicious case. 688 
In addition to an overall cancer likelihood score, the AI system emits a ranked list of rectangular 689 
bounding boxes for each case. To conduct a fair comparison, we allowed the AI system only its 690 
top two bounding boxes to match the number of ROIs produced by the readers. 691 
 692 
To compare the localisation performance of the AI system with that of the readers, we used a 693 
method inspired by location receiver operating characteristic (LROC) analysis37. LROC analysis 694 
differs from traditional ROC analysis in that the ordinate is a sensitivity measure that factors in 695 
localisation accuracy. Although LROC analysis traditionally involves a single finding per 696 
case37,47, we permitted multiple unranked findings to match the format of our data. We use the 697 
term multi-localization ROC analysis (mLROC) to describe our approach. For each threshold, a 698 
cancer case was considered a true positive if its casewide score exceeded this threshold and at 699 
least one culprit area was correctly localised in any of the four mammogram views. Correct 700 
localisation required an intersection-over-union (IoU) of 0.1 with the ground truth ROI. False 701 
positives were defined as usual.  702 
 703 
CAD systems are often evaluated on the basis of whether the center of their marking falls within 704 
the boundary of a ground truth annotation48. This is potentially problematic since it doesn’t 705 
properly penalize predicted bounding boxes that are so large as to be nonspecific, but whose 706 
center nevertheless happens to fall within the target region. Similarly, large ground truth 707 
annotations associated with diffuse findings might be overly generous to the CAD system. We 708 
prefer the IoU metric because it balances these considerations. We chose a threshold of 0.1 to 709 
account for the fact that indistinct margins on mammography findings lead to region-of-interest 710 
annotations of vastly different sizes depending on subjective factors of the annotator. See 711 
Supplementary Figure 4. Similar work in 3D chest computed tomography 18 used any pixel 712 





fracture detection reports statistics in which true positives require at least one pixel of overlap 49. 714 
An IoU value of 0.1 is strict by these standards. 715 
 716 
Statistical analysis. To evaluate standalone AI system performance, the area under the ROC 717 
curve was estimated using the normalized Wilcoxon (Mann-Whitney) U statistic50. This is the 718 
standard nonparametric method employed by most modern software libraries. For the UK 719 
dataset, nonparametric confidence intervals on the AUC were computed with DeLong's method 720 
51,52. For the US dataset, in which each sample carried a scalar weight, the bootstrap was used 721 
with 1000 replications. 722 
 723 
On both datasets, we compared the sensitivity and specificity of the readers with that of a 724 
thresholded score from the AI system. For the UK dataset, we knew the identity of each reader, 725 
so statistics were adjusted for the clustered nature of the data using Obuchowski's method for 726 
paired binomial proportions53,54. Confidence intervals on the difference are Wald intervals 55 and 727 
a Wald test was used for noninferiority 56. Both used the Obuchowski variance estimate. 728 
 729 
For the US dataset, in which each sample carried a scalar inverse probability weight45, we used 730 
resampling methods 57 to compare the AI system's sensitivity and specificity with that of the pool 731 
of radiologists. Confidence intervals on the difference were generated with the bootstrap method 732 
with 1000 replications. A p-value on the difference was generated through the use of a 733 
permutation test 58. In each of 10000 trials, the reader and AI system scores were randomly 734 
interchanged for each case, yielding a reader-AI system difference sampled from the null 735 
distribution. A two-sided p-value was computed by comparing the observed statistic to the 736 
empirical quantiles of the randomization distribution. 737 
 738 
In the reader study, each reader graded each case using a forced BI-RADS protocol (a score of 739 
0 was not permitted), and the resulting values were treated as a 6-point index of suspicion for 740 
malignancy. Scores of 1 and 2 were collapsed into the lowest category of suspicion; scores 3, 741 
4a, 4b, 4c, and 5 were treated independently as increasing levels of suspicion. Because none of 742 
the BI-RADS operating points reached the high sensitivity regime (see Figure 3), to avoid bias 743 
from nonparametric analysis 59 we fit parametric ROC curves to the data using the proper 744 
binormal model 60. This issue was not alleviated by using the readers' malignancy suspicion 745 
ratings, which showed very strong correspondence with the BI-RADS scores (Supplementary 746 
Figure 5). Since BI-RADS is used in actual screening practice, we elected to focus on these 747 
scores for their superior clinical relevance. In a similar fashion, we fit a parametric ROC curve to 748 
discretized AI system scores on the same data. 749 
 750 
The performance of the AI system was compared to that of the panel of radiologists using 751 
methods for the analysis of multi-reader multi-case (MRMC) studies standard in the radiology 752 
community 61. More specifically, we compared the AUC-ROC and pAUC-mLROC for the AI 753 
system to that of the average radiologist using the ORH procedure, which was proposed in 62 754 
and updated in 63. Originally formulated for the comparison of multiple imaging modalities, this 755 
analysis has been adapted to the setting in which the population of radiologists operate on a 756 





algorithm 61. The jackknife method was used to estimate the covariance terms in the model. The 758 
p-value and confidence interval computation was conducted in Python using the numpy and 759 
scipy packages and benchmarked against a reference implementation in the RJafroc library for 760 
the R computing language 64. 761 
 762 
Our primary comparisons numbered seven in total: sensitivity and specificity for the UK first 763 
reader; sensitivity and specificity for the US clinical radiologist; sensitivity and specificity for the 764 
US clinical radiologist using a model trained using only UK data; and the AUC-ROC in the 765 
reader study. For comparisons with the clinical reads, the choice of superiority or non-inferiority 766 
was based on what seemed attainable from simulations conducted on the validation set. For 767 
non-inferiority comparisons, a 5% absolute margin was prespecified before inspecting the test 768 
set. We employed a statistical significance threshold of 0.05. All seven p-values survived 769 
correction for multiple comparisons using the Holm-Bonferroni method65. 770 
 771 
Code availability. The code used for training the models has a large number of dependencies 772 
on internal tooling, infrastructure and hardware, and its release is therefore not feasible. 773 
However, all experiments and implementation details are described in sufficient detail in the 774 
Supplementary Methods section to allow independent replication with non-proprietary libraries. 775 
Several major components of our work are available in open source repositories: Tensorflow: 776 
https://www.tensorflow.org; Tensorflow Object Detection API: 777 
https://github.com/tensorflow/models/tree/master/research/object_detection 778 
 779 
Data availability. The dataset from Northwestern Medicine was used under license for the 780 
current study, and is not publicly available. Applications for access to the OPTIMAM database 781 
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Extended Data Tables 883 
Extended Data Table 1. Characteristics of the UK and UK test sets.  For each feature, we 884 
constructed a joint 95% confidence interval on the proportions in each category. a, The UK test 885 
set was drawn from two sites in the UK over a four-year period. For reference, we present the 886 
corresponding statistics from the broader UK Breast Screening Programme (BSP)66.  For 887 
comparison with national numbers, only screen-detected cancers are reported here. b, The US 888 
test was drawn from one academic medical center over an eighteen-year period. For reference, 889 
we present the corresponding statistics from the broader US screening population, as reported 890 
by the Breast Cancer Surveillance Consortium (BCSC)2. Cancers reported here occurred within 891 
12 months of screening.  892 
 893 
Extended Data Table 2. Detailed comparison between human clinical decisions and AI 894 
predictions. 895 
a. Comparison of sensitivity and specificity between human benchmarks, derived retrospectively 896 
from the clinical record, and the predictions of the AI system. Score thresholds were chosen, 897 
based on separate validation data, to match or exceed the performance of each human 898 
benchmark (Methods, Operating point selection). These points are depicted graphically in 899 
Figure 2a. Bolded quantities represent estimated differences which are statistically significant 900 
for superiority; all others are statistically noninferior at a prespecified 5% margin. Note that the 901 
number of cases (N) differs from Figure 2a because a radiologist opinion was not available for 902 
all images. We also note that sensitivity and specificity metrics are not easily comparable to 903 
most prior publications in breast imaging (eg. the DMIST Trial 34) given differences in follow up 904 
interval. Negative cases in the US dataset were upweighted to account for the sampling protocol 905 
(Methods, Inverse probability weighting). 906 
b. Same columns as A, but using a version of the AI system trained exclusively on the UK 907 
dataset. It was tested on the US dataset to show generalisability of the AI across different 908 
populations and healthcare systems. Superiority comparisons on the UK data were conducted 909 
using Obuchowski’s extension of the two-sided McNemar test for clustered data. Noninferiority 910 
comparisons were Wald tests using the Obuchowski correction. Comparisons on the US data 911 
were performed with a two-sided permutation test. All p-values survived correction for multiple 912 
comparisons (Methods, Statistical analysis). 913 
 914 





Extended Data Table 3. Detailed description of reader study case composition. 916 
Row 1. 500 cases were selected for the reader study. The case mixture was enriched for 917 
positives as well as challenging negatives. 918 
Row 2. Cases containing breast implants and those for which at least half of the readers 919 
indicated image quality concerns were excluded from analysis. The remaining 465 cases are 920 
represented in Figure 3a and b. 921 
Row 3. We also restricted the cancers to those that developed within 12 months. Those that 922 
developed cancer later (but within 27 months) were excluded because they did not meet the 923 
follow-up criteria to be considered negative. The remaining 408 cases are represented in 924 
Extended Data Table 2c and Extended Data Figure 2. 925 
Row 4. To perform localisation analysis, the areas of malignancy were determined using follow-926 
up biopsy data. In three instances, ground truth could not reliably be determined. The remaining 927 
405 cases are represented in Extended Data Figure 3. 928 
 929 
Extended Data Table 4. Potential utility of the AI system in two clinical applications. 930 
a. Simulation using the UK test set in which the AI system is used in place of the second reader 931 
when it concurs with the first reader. In cases of disagreement (12.02%) the consensus opinion 932 
was invoked. The high performance of this combination of human and machine suggests that 933 
approximately 88% of the second reader’s effort can be eliminated while maintaining the 934 
standard of care produced by double reading. The AI system’s decision was generated using 935 
operating point (i) in Figure 2a. Confidence intervals are Wald intervals computed with the 936 
Obuchowski correction for clustered data. 937 
b. Evaluation of the AI system for low-latency triage. Operating points were set to perform with 938 
high NPV and PPV for detecting cancer in 12 months.  939 
 940 
Extended Data Table 5. Discrepancies between the AI system and human readers. 941 
For the UK comparison, we used the first reader operating point (i) shown in Figure 2a. For the 942 
US comparison, we used the operating point shown in Figure 2b. 943 
 944 
Extended Data Table 6. Performance breakdowns. Analysis excludes technical recalls and 945 
US cases for which BI-RADS scores were unavailable. 946 
a. Sensitivity across cancer subtypes in the UK data. We used the AI system operating point (i) 947 
in Figure 2a. Also shown is the first reader performance on the same subset. 948 
b. Sensitivity across cancer subtypes in the US data. We used the AI system operating point (i) 949 
in Figure 2a. Reader performance was derived from the clinical BI-RADS scores on the same 950 
subset. ILC = Invasive lobular carcinoma, IDC = invasive ductal carcinoma, DCIS = ductal 951 
carcinoma in situ.  952 
c. Performance across breast density categories. BI-RADS35 breast density was extracted from 953 
the radiology report rendered at the time of screening, only available in the US dataset. We 954 
used the AI system operating point shown in Figure 2b. Adjusted specificities were computed 955 
using inverse probability weighting (Methods). 956 
 957 





Extended Data Table 7. Reader experience from the UK clinical dataset (a) and the 959 
independent reader study (b). 960 
 961 
Extended Data Figures 962 
Extended Data Figure 1. Unweighted evaluation of breast cancer prediction on the US 963 
test set. Unlike in Figure 2b, the sensitivity and specificity were computed without the use of 964 
inverse probability weights to account for the spectrum-enrichment of the study population. 965 
Since hard negatives are overrepresented, the specificity of both the AI system and the human 966 
readers is reduced. The unweighted human sensitivity and specificity are 48.10% (n = 553) and 967 
69.65% (n = 2,185), respectively. 968 
 969 
Extended Data Figure 2. Breast cancer prediction performance compared to six 970 
independent readers with a 12-month follow up for cancer status. While the mean reader 971 
AUC was 0.750 (s.d. 0.049), the AI system achieved an AUC of 0.871 (95% CI: [0.785, 0.919]). 972 
The AI system exceeded human performance by a significant margin (∆ = +0.121, 95% CI: 973 
[0.070, 0.173], p = 0.0018, two-sided ORH method). In this analysis, there were 56 positives of 974 
408 total cases; see Extended Data Table 3. Note that this sample of cases was enriched for 975 
patients that had received a negative biopsy result (n=119), making this a more challenging 976 
population for screening. Since these external readers were not gatekeepers for follow up and 977 
eventual cancer diagnosis, there was no bias in favour of reader performance at this shorter 978 
time horizon. See Figure 3A for a comparison with a time interval chosen to encompass a 979 
subsequent screening exam.  980 
 981 
Extended Data Figure 3. Multi-location receiver operating characteristic (mLROC) 982 
analysis.  983 
Similar to Extended Data Figure 2, but true positives require localisation of a malignancy in any 984 
of the four mammogram views (Methods, Localisation analysis). Here, the cancer interval was 985 
12 months (n = 53 positives of 405 cases; see Extended Data Table 3). The dotted line 986 
indicates a false positive rate of 10%, which was used as the right-hand boundary for the partial 987 
AUC (pAUC) calculation. The mean reader pAUC was 0.029 (s.d. 0.005), while the AI system's 988 
pAUC was 0.048 (95% CI: [0.035, 0.061]). The AI system exceeded human performance by a 989 
significant margin (∆ = +0.0192, 95% CI: [0.0086, 0.0298], p = 0.0004, two-sided ORH method). 990 
 991 
Extended Data Figure 4. Evidence for the gatekeeper effect in retrospective datasets. 992 
These figures show the change in observed reader sensitivity in the UK (a) and the US (b) as 993 
the cancer follow-up interval is extended. At short intervals, measured reader sensitivity is 994 
extremely high, owing to the fact that biopsies are only triggered based on radiological 995 
suspicion. As the time interval is extended, the task becomes more difficult and measured 996 
sensitivity declines. Part of this decline stems from the development of new cancers that were 997 
impossible to detect at initial screening. However, more precipitous drops occur when the 998 





in the US). This is suggestive of what happens to reader metrics when gatekeeper bias is 1000 
mitigated by another screening examination. 1001 
 1002 
Extended Data Figure 5. Quantitative evaluation of reader and AI system performance 1003 
with a 12-month follow-up interval for ground truth cancer positive status.  1004 
Because a 12-month follow-up interval is unlikely to encompass a subsequent screening exam 1005 
in either country, reader-model comparisons on retrospective clinical data may be contaminated 1006 
by the gatekeeper effect (Extended Data Figure 4). See Figure 2 for comparison with longer 1007 
time intervals.  1008 
a. AI system performance on UK data. This plot was derived from a total of 25,717 eligible 1009 
examples including 274 positives. The AI system achieved an AUC of 0.966 ([0.954, 0.977], 1010 
95% CI). 1011 
b. AI system performance on US data. This plot was derived from a total of 2,770 eligible 1012 
examples including 359 positives. The AI system achieved an AUC of 0.883 ([0.859, 0.903], 1013 
95% CI). 1014 
c. Reader performance. In computing reader metrics on the UK data, we excluded cases for 1015 
which the reader recommended repeat mammography to address technical issues. In the US 1016 
data, radiologist performance could only be assessed on the subset of cases for which a BI-1017 
RADS grade was available. 1018 
 1019 
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